EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients

Francesca Parisi, Giuseppa De Luca, Manuela Mosconi, Sonia Lastraioli, Chiara Dellepiane, Giovanni Rossi, Silvia Puglisi, Elisa Bennicelli, Giulia Barletta, Lodovica Zullo, Sara Santamaria, Marco Mora und 13 weitere

Cancer Treatment and Research Communications · 2024

DOI: 10.1016/j.ctarc.2024.100839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2024. Verfasst von Francesca Parisi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2 Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Molecular characterization is pivotal for managing non-small cell lung cancer (NSCLC), although this process is often time-consuming and patients' conditions might worsen while molecular analyses are processed. Our primary aim was to evaluate the performance of "up-front" next-generation sequencing (NGS) through liquid biopsy (LB) of hospitalized patients with newly detected lung neoplasm in parallel with conventional diagnosis. The secondary aim included longitudinal monitoring through LB of patients with oncogenic alterations at baseline. METHODS: We enrolled 47 consecutive patients immediately after hospitalization and radiological detection of symptomatic lung neoplasm. LB from peripheral blood was performed at baseline, in parallel with conventional biopsy (CB), when feasible. Additionally, LBs were repeated during treatment in patients with actionable gene alterations at baseline. Oncomine™ Lung cfTNA Research Assay panel was employed for processing plasma samples in NGS. RESULTS: 47 hospitalized patients were enrolled. LB identified 28 patients with gene alterations, including mutations of EGFR (n = 7), KRAS (n = 12), ERBB2 (n = 1), TP53 (n = 2), BRAF (n = 1), one ALK rearrangement, and 4 patients with combined mutations involving EGFR, KRAS and PIK3CA. LB and CB were consistent, except for two patients. Three patients with positive LB for oncogenic drivers did not undergo CB due to contraindications. Median time to molecular results after LB was significantly lower compared to time to molecular report after CB (11 versus 22 days, p < 0.001). CONCLUSIONS: Despite limited numbers, our study supports the role of front-line LB for improving management of symptomatic patients with lung cancer, potentially leading to early targeted therapy initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyMaleFemaleMiddle AgedAgedMutationHospitalizationBiomarkers, TumorAged, 80 and overAdult

Stichwörter der Autor:innen

EGFREmergency departmentLiquid biopsyLung cancerTargeted therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Medical Oncology 2 Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Pathological Anatomy Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Department of Internal Medicine and Medical Specialties, University of Genoa, Italy; Academic Internal Medicine with Oncology Focus Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Förderung

  • Ministero della Salute

Zitieren

APA

Parisi, F., De Luca, G., Mosconi, M., Lastraioli, S., Dellepiane, C., Rossi, G., Puglisi, S., Bennicelli, E., Barletta, G., Zullo, L., Santamaria, S., Mora, M., Ballestrero, A., Montecucco, F., Bellodi, A., Del Mastro, L., Lambertini, M., Barisione, E., Cittadini, G., …, & Genova, C. (2024). Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2024.100839

Vancouver

Parisi F, De Luca G, Mosconi M, Lastraioli S, Dellepiane C, Rossi G, et al. Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients. Cancer Treatment and Research Communications. 2024. doi:10.1016/j.ctarc.2024.100839

BibTeX
@article{Parisi2024,
  author = {Parisi, Francesca and De Luca, Giuseppa and Mosconi, Manuela and Lastraioli, Sonia and Dellepiane, Chiara and Rossi, Giovanni and Puglisi, Silvia and Bennicelli, Elisa and Barletta, Giulia and Zullo, Lodovica and Santamaria, Sara and Mora, Marco and Ballestrero, Alberto and Montecucco, Fabrizio and Bellodi, Andrea and Del Mastro, Lucia and Lambertini, Matteo and Barisione, Emanuela and Cittadini, Giuseppe and Tagliabue, Elena and Spagnolo, Francesco and Tagliamento, Marco and Coco, Simona and Dono, Mariella and Genova, Carlo},
  title = {Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients},
  journal = {Cancer Treatment and Research Communications},
  year = {2024},
  doi = {10.1016/j.ctarc.2024.100839}
}
Kostenlos starten →